CN109563090A - 二氮杂-苯并荧蒽类化合物的盐型和晶型 - Google Patents

二氮杂-苯并荧蒽类化合物的盐型和晶型 Download PDF

Info

Publication number
CN109563090A
CN109563090A CN201780048973.4A CN201780048973A CN109563090A CN 109563090 A CN109563090 A CN 109563090A CN 201780048973 A CN201780048973 A CN 201780048973A CN 109563090 A CN109563090 A CN 109563090A
Authority
CN
China
Prior art keywords
crystal form
compound
formula
ray powder
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780048973.4A
Other languages
English (en)
Other versions
CN109563090B (zh
Inventor
陆青青
施沈
施沈一
白铁忠
袁淑杰
李郑武
户巧芬
曹翊婕
高晶
丁辉
李金花
徐光海
王峥
金鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin Pharmaceutical Group Co ltd General Pharmaceutical Factory
Original Assignee
Harbin Pharmaceutical Group Co ltd General Pharmaceutical Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbin Pharmaceutical Group Co ltd General Pharmaceutical Factory filed Critical Harbin Pharmaceutical Group Co ltd General Pharmaceutical Factory
Publication of CN109563090A publication Critical patent/CN109563090A/zh
Application granted granted Critical
Publication of CN109563090B publication Critical patent/CN109563090B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D461/00—Heterocyclic compounds containing indolo [3,2,1-d,e] pyrido [3,2,1,j] [1,5]-naphthyridine ring systems, e.g. vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Battery Electrode And Active Subsutance (AREA)

Abstract

本发明公开了化合物1的盐酸盐、柠檬酸盐、磷酸盐或硫酸盐，及上述盐的晶型及其制备方法，以及它们在制备治疗脑卒中或癫痫药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201780048973.4A 2016-08-04 2017-08-03 二氮杂-苯并荧蒽类化合物的盐型和晶型 Active CN109563090B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016106336227 2016-08-04
CN201610633622 2016-08-04
PCT/CN2017/095762 WO2018024225A1 (zh) 2016-08-04 2017-08-03 二氮杂-苯并荧蒽类化合物的盐型和晶型

Publications (2)

Publication Number Publication Date
CN109563090A true CN109563090A (zh) 2019-04-02
CN109563090B CN109563090B (zh) 2021-02-23

Family

ID=61073724

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780048973.4A Active CN109563090B (zh) 2016-08-04 2017-08-03 二氮杂-苯并荧蒽类化合物的盐型和晶型

Country Status (14)

Country Link
US (1) US11124506B2 (zh)
EP (1) EP3495361B1 (zh)
JP (1) JP6977236B2 (zh)
KR (1) KR102275415B1 (zh)
CN (1) CN109563090B (zh)
AU (1) AU2017306606B2 (zh)
BR (1) BR112019002216A2 (zh)
ES (1) ES2837573T3 (zh)
IL (1) IL264651B (zh)
PH (1) PH12019500248A1 (zh)
RU (1) RU2762189C2 (zh)
UA (1) UA122731C2 (zh)
WO (1) WO2018024225A1 (zh)
ZA (1) ZA201901155B (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268245A2 (en) * 1986-11-17 1988-05-25 Sanwa Kagaku Kenkyusho Co., Ltd. Process for the preparation of eburnamenine oxime derivatives
WO2013076646A1 (en) * 2011-11-22 2013-05-30 Richter Gedeon Nyrt. A new diaza-benzofluoranthene derivative as drug
WO2016124129A1 (zh) * 2015-02-04 2016-08-11 南京明德新药研发股份有限公司 二氮杂-苯并荧蒽类化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166474B (zh) * 1971-11-03 1975-03-28
DE3479423D1 (en) * 1984-02-29 1989-09-21 Covex Sa Citrate of vinpocetine, and process for its preparation
ES2097703B1 (es) * 1995-04-12 1997-12-01 Decox S L Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268245A2 (en) * 1986-11-17 1988-05-25 Sanwa Kagaku Kenkyusho Co., Ltd. Process for the preparation of eburnamenine oxime derivatives
WO2013076646A1 (en) * 2011-11-22 2013-05-30 Richter Gedeon Nyrt. A new diaza-benzofluoranthene derivative as drug
WO2016124129A1 (zh) * 2015-02-04 2016-08-11 南京明德新药研发股份有限公司 二氮杂-苯并荧蒽类化合物

Also Published As

Publication number Publication date
JP6977236B2 (ja) 2021-12-08
EP3495361A4 (en) 2019-06-12
BR112019002216A2 (pt) 2019-05-14
UA122731C2 (uk) 2020-12-28
PH12019500248A1 (en) 2019-10-21
IL264651A (zh) 2019-04-30
US20190169183A1 (en) 2019-06-06
RU2762189C2 (ru) 2021-12-16
EP3495361B1 (en) 2020-10-28
AU2017306606B2 (en) 2020-04-30
CN109563090B (zh) 2021-02-23
EP3495361A1 (en) 2019-06-12
KR20190035854A (ko) 2019-04-03
RU2019105922A3 (zh) 2020-09-04
RU2019105922A (ru) 2020-09-04
KR102275415B1 (ko) 2021-07-09
AU2017306606A8 (en) 2019-12-05
ES2837573T3 (es) 2021-06-30
IL264651B (en) 2022-08-01
AU2017306606A1 (en) 2019-03-21
JP2019523306A (ja) 2019-08-22
US11124506B2 (en) 2021-09-21
ZA201901155B (en) 2020-10-28
WO2018024225A1 (zh) 2018-02-08

Similar Documents

Publication Publication Date Title
EP3546460B1 (en) Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof
TWI827017B (zh) 吡啶衍生物及其在醫藥上的應用
CN105163738A (zh) Mk2抑制剂和其用途
KR20130122778A (ko) FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체
CN103396396B (zh) 胺基烷酰克林沙星及其应用
WO2019154395A1 (zh) 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN103068804B (zh) 作为kcnq2/3调节剂的取代的2-氧基-喹啉-3-甲酰胺
CN105705493A (zh) 喹唑啉衍生物、其制备方法、药物组合物和应用
US11034670B2 (en) Poly-ADP ribose polymerase (PARP) inhibitors
CN103459388B (zh) 新型呋喃酮衍生物
CN106928252B (zh) 一种抑制rock的化合物及其制备方法与应用
CN109563090A (zh) 二氮杂-苯并荧蒽类化合物的盐型和晶型
EA007226B1 (ru) Производные имидазохинолина
CN115785088A (zh) 作为sos1抑制剂的化合物及其应用
CN109134433A (zh) 一种抑制rock的化合物及其应用
CN110650961A (zh) Parp抑制剂、其药物组合物、制备方法和应用
US11993585B2 (en) Poly-ADP ribose polymerase (PARP) inhibitors
CN115109040A (zh) 抗真菌化合物，包含其的药物组合物和制剂，及其应用
CN115703738A (zh) 含2-芳杂环取代的脲类化合物、其制备方法和用途
CN117088887A (zh) Shp2抑制剂及其用途
WO2024109945A1 (en) Selenium containing heterocycle compounds and use thereof
US20220411430A1 (en) Substituted imidazolecarboxamide as bruton's tyrosine kinase inhibitors
CN111440177A (zh) 一种新型取代吡唑并[1,5-a]嘧啶类化合物及其制备方法和应用
CN115322208A (zh) 一类新型的2-氨基噻唑类衍生物及其制备方法和医药用途
CN113840605A (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式，及其制备方法和治疗用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant